Pembro Plus Chemo Now for First-Line Metastatic Squamous NSCLC

Share this post

The FDA has granted approval for immunotherapy with pembrolizumab in combination with chemotherapy to be used first-line in metastatic squamous nonsmall cell lung cancer.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply